RATIONAL DESIGNING OF SUSTAINED RELEASE MATRIX FORMULATION OF ETODOLAC EMPLOYING HYPROMELLOSE, CARBOMER, EUDRAGIT AND POVIDONE
Objective: The existing investigation represents a challenge in formulating etodolac oral controlled release tablets employing five most prominent hydrophilic release rate retardant polymers like HPMC K100M, HPMC K4M, Carbopol 934P, Eudragit RS100, and Polyvinyl pyrrolidone K90 which are USFDA approved non-toxic substances, cost-effective, and easily available.
Methods: The tablets were manufactured by wet granulation method along with talc, anhydrous lactose, and magnesium stearate. The pre-compression attributes of the produced granules and the post-compression characteristics were assessed according to the specified protocols. The formulations were accessed for their ability to release the drug in the simulated gastric media and the obtained results were fitted into various kinetic models to determine the probable drug release mechanism(s). A short-term stability study (for 90 days duration) was also performed.
Results: The prepared granules demonstrated superior flow properties and packing ability, whereas the fabricated sustained release matrix batches showed excellent mechanical characteristics. The in vitro drug release profile of the hypromellose, carbomer, eudragit and povidone based sustained release matrix tablet formulations expressed drug release for the period of 12 hr following the diffusion cum erosion mechanism(s) (termed as anomalous diffusion) and illustrated comparable drug release with that of marketed formulation (EtogesicÂ®-ER 600 mg). The produced formulations revealed splendid reproducibility and stability under accelerated conditions.
Conclusion: The judiciously planned fabrication of the matrix formulations possess the ability to decrease the frequency of drug administration to twice-daily along with minimizing the blood level fluctuations, which ultimately leads to enhanced patient compliance and better therapeutic regimens.
2. Pilli R, Nagabhushanam MV, Kadali SK. Etodolac dissolution improvement by preparation of solid dispersions with cyclodextrin complexes. Int J Pharm Sci Res 2014;5:4774-91.
3. Kumar BP, Sumalatha YS. Formulation development and evaluation of floating tablets of etodolac. World J Pharm Pharm Sci 2015;4:1516-32.
4. Ibrahim MM, Mohamed EN, El-Setouhy DA, Fadlalla MA. Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation. AAPS PharmSciTech 2010;11:1730-7.
5. Dangre PV, Godbole MD, Ingale PV, Mahapatra DK. Improved dissolution and bioavailability of eprosartan mesylate formulated as solid dispersions using conventional methods. Indian J Pharm Edu Res 2016;50:S209-S217.
6. Panchal KK, Chotai NP. Formulation development and in vitro evaluation of controlled release matrix tablet of etodolac. Indian J Pharm Edu Res 2013;47:39-48.
7. Shetty P, Kumar R, Suvarna P, Swamy VB. Design and evaluation of sustained release matrix tablets of etodolac. Asian J Pharm Tech 2016;6:1-4.
8. Patil MD, Mahapatra DK, Dangre PV. Formulation and in vitro evaluation of once-daily sustained release matrix tablet of nifedipine using rate retardant polymers. Inventi PharmTech 2016;4:1-7.
9. Godbole MD, Mahapatra DK, Khode PD. Fabrication and characterization of the edible jelly formulation of stevioside: a nutraceutical or OTC aid for the diabetic patients. Inventi Nutraceut 2017;2:1-9.
10. Sonkusre N, Dhabarde DM, Mahapatra DK. Formulation and development of mirtazapine self-emulsifying drug delivery system (SEDDS) for enhancement of dissolution profile. Inventi NDDS 2016;3:1-9.
11. Arumugarajan AK, Geetha G, Nayak BS. Preparation and in vitro evaluation of etodolac extended-release tablets prepared by wet granulation method employing KollidonÂ® SR. Indo Am J Pharm Sci 2015;2:1133-40.
12. Sandhya P, Habeeb S, Sunitha M, Patnaik KSKR, Subrahmanyam CVS. A novel approach in modified release dosage forms formulation and evaluation of oral controlled release matrix tablets of etodolac. Asian J Pharm Res 2013;3:60-5.
13. Panchal KK, Chotai NP. Formulation development and in vitro evaluation of controlled release matrix tablet of etodolac. Indian J Pharm Edu Res 2013;47:39-48.
14. Shetty P, Kumar R, Yamunappa, Suvarna P, Narayana SVB. Design and evaluation of sustained release matrix tablets of etodolac. Asian J Pharm Tech 2016;6:1-14.